The first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating Enhertu in combination with rilvegostomig or pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab as a first-line therapy in patients with HER2 expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer. DESTINY-Endometrial01 will be conducted in collaboration with The GOG Foundation, Inc. and the European Network of Gynecological Oncological Trial.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- IonQ announces results from pact with AstraZeneca, Amazon.com and Nvidia
- Study finds GLP-1s may have link to eye disease, STAT reports
- AstraZeneca’s Calquence approved in EU for treating CLL
- Vaccine opponent hired by RFK Jr. searches CDC record for autism link, WSJ says
- AstraZeneca’s Promising Outlook: Buy Rating Backed by Positive DESTINY-Breast09 Trial Results and 35.5% Upside Potential